Mesenteric Ischemia Markers Study
ConditionMesenteric Vascular Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBelarusian State Medical University
About this trial
Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.
Eligibility criteria
Qualifiers
18 years or older, all sex
Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases
Patient's consent to participate in the study
No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).
Disqualifiers
Consent declined by patient or relatives
Failure to meet inclusion criteria
Trial design
Treatments tested in this trial
- Blood samples
Treatment groups
120 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov